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Neurofibromatosis type 1 (NF1), a neuroectodermal disorder, is caused by germline mutations in the NF1 gene. NF1
affects approximately 1/3,000 individuals worldwide, with about 50% of cases representing de novo mutations.
Although the NF1 gene was identified in 1990, the underlying gene mutations still remain undetected in a small
but obdurate minority of NF1 patients. We postulated that in these patients, hitherto undetected pathogenic
mutations might occur in regulatory elements far upstream of the NF1 gene. In an attempt to identify such
remotely acting regulatory elements, we reasoned that some of them might reside within DNA sequences that (1)
have the potential to interact at distance with the NF1 gene and (2) lie within a histone H3K27ac-enriched region, a
characteristic of active enhancers. Combining Hi-C data, obtained by means of the chromosome conformation
capture technique, with data on the location and level of histone H3K27ac enrichment upstream of the NF1 gene,
we predicted in silico the presence of two remotely acting regulatory regions, located, respectively, approximately
600 kb and approximately 42 kb upstream of the NF1 gene. These regions were then sequenced in 47 NF1 patients
in whom no mutations had been found in either the NF1 or SPRED1 gene regions. Five patients were found to
harbour DNA sequence variants in the distal H3K27ac-enriched region. Although these variants are of uncertain
pathological significance and still remain to be functionally characterized, this approach promises to be of general
utility for the detection of mutations underlying other inherited disorders that may be caused by mutations in
remotely acting regulatory elements.
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Germline mutations of the NF1 gene cause the tumour
predisposition syndrome, neurofibromatosis type 1 (NF1),
which affects 1/3,000–4,000 individuals worldwide. The
NF1 gene, spanning 283 kb on chromosome 17q11.2,
contains 61 exons that give rise to a 12-kb mRNA transcript
encoding neurofibromin [1,2]. The 327-kDa (2,818-amino
acid) protein product, neurofibromin, is expressed in
most tissues.
Neurofibromin is a tumour suppressor protein, reflecting
its role as a key negative regulator of the cellular Ras
signalling pathway (reviewed by Bennett et al. [3]).
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reproduction in any medium, provided the orprotein (GAP), with strong structural and sequence
homologies to the GAP superprotein family [4]. It functions
by downregulating Ras, thereby resulting in an overall
reduction in cellular mitogenic signalling via the Ras
pathway. Thus, any NF1 gene mutation that serves to
inactivate neurofibromin function may be expected to
increase cellular levels of active Ras-GTP significantly,
leading to uncontrolled cell growth and, potentially,
tumorigenesis [5]. Germline mutations in the SPRED1
gene have previously been detected in individuals with
clinical features overlapping those of NF1 patients [6].
Consistent with Knudson's two-hit hypothesis, NF1
patients harbouring a heterozygous germline NF1 mutation
develop neurofibromas upon somatic mutation of the second
wild-type NF1 allele. The somatic loss of the second NF1
allele in the progenitor cell (either the Schwann cell or its
precursor), combined with haploinsufficiency in a varietyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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formation. The mutation rate at the NF1 locus is one of
the highest reported in any human disorder [8]; almost
50% of all NF1 patients exhibit a de novo NF1 mutation.
The NF1 mutational spectrum is shaped in large part,
and often in remarkably predictable ways, by the local
DNA sequence environment [9]. Nearly 1,300 different
inherited mutations of the NF1 gene have been reported
as a cause of NF1; these vary in size from deletions
spanning more than a megabase to subtle single base-pair
substitutions that alter an encoded amino acid or the
function of a splice junction [9]. In classical NF1 patients,
NF1 gene mutations are detectable in 50% to 95% of
individuals depending upon the mutation detection
techniques employed and the source of tissue used for
analysis [2,10]. In our own study, the underlying patho-
genic NF1 mutation was detected in approximately 92%
of NF1 patients despite sequencing the exons, splice
junctions, untranslated regions and proximal promoter
region of the NF1 gene, and screening for gross gene
deletions and rearrangements as well as subtle lesions
[11-13]. The undetected mutations in such patients could
in principle reside within a remote regulatory element
at some distance from the NF1 gene.
In the human genome, not all regulatory elements
occur immediately 5′ to the genes that they regulate;
indeed, some are located at considerable distances from
their cognate genes. A variety of micro-lesions causing
human inherited disease have been found to occur >10
kb 5′ upstream of the corresponding disease genes [14].
These include a total of eight mutations within a 1-kb
region (termed the long-range or limb-specific enhancer,
ZRS) approximately 979 kb 5′ to the transcription initi-
ation site of the sonic hedgehog (SHH) gene [15]. Far
upstream polymorphic variants that influence gene expres-
sion and impact on disease have also been documented.
Thus, for example, the C>T functional single nucleotide
polymorphism (SNP) 14.5 kb upstream of the interferon
regulatory factor 6 (IRF6) gene, which is associated with
cleft palate, alters the binding of transcription factor AP-2α
[16]. Similarly, a T>C functional SNP approximately 6 kb
upstream of the α-globin-like HBM gene serves to create
a binding site for the erythroid-specific transcription
factor GATA1 and interferes with the activation of the
downstream α-globin genes [17]. Finally, a T>G functional
SNP approximately 335 kb upstream of the MYC gene
increases the risk of colorectal and prostate cancer by
altering the binding strength of transcription factors TCF4
and/or TCF7L2 within a transcriptional enhancer [18]. On
the basis of these findings in a number of different genes,
we postulated that remotely acting regulatory elements
might be present far upstream of the NF1 gene and that
these could be mutated in NF1 patients in whom no
pathogenic mutations had been detected.The NF1 gene contains a TATA-less promoter within
a classic CpG island that extends from the proximal pro-
moter into exon 1, and a 454-bp 5′ untranslated region
[19]. The CpG island is normally unmethylated, and the
gene is actively transcribed in all tissues so far examined.
Despite the high degree of conservation of the proximal
regulatory sequences in rodent orthologs [20,21], the distal
upstream sequence, potentially harbouring additional regu-
latory elements, diverges quite significantly between differ-
ent mammalian species.
Histone H3K27ac serves to distinguish active enhancers
from inactive ones [22]. Information on various functional
elements, including regions enriched in histone H3K27ac,
encoded by the human genome, have recently become
available through the ENCODE project resources (EN-
CODE Project Consortium 2011 [23]; http://genome.ucsc.
edu/index.html), a comprehensive collection of experimen-
tal data produced using biochemical assays mapped to
human genome data. Using a variety of high-throughput
techniques for identifying features characteristic to en-
hancers (e.g. specific histone modifications), up to 1.4 mil-
lion putative enhancers have been identified in the human
genome [23,24].
It has long been hypothesized that communication
between widely spaced genomic elements is facilitated
by the spatial organization of chromosomes that brings
genes and their cognate regulatory elements into close
spatial proximity [25]. The development of ‘chromosome
conformation capture’ techniques has led to the discovery
of many long-range interactions, both intra- and inter-
chromosomal (reviewed in [26]). Recently, Lieberman-
Aiden et al. [27] employed a novel approach, based on
chromosomal conformation capture techniques, and termed
Hi-C, to probe the 3D architecture of the entire human
genome by coupling proximity-based ligation with massively
parallel sequencing to produce a catalogue of approximately
8.4 million inter- and intra-chromosomal interacting frag-
ments. Approximately 6.7 million of these fragments were
found to be of long range (>20 kb apart). A genome-wide
matrix of DNA-DNA interactions (also known as a contact
map), created by dividing the genome into 1-Mb regions
and counting the number of interactions between these 1-
Mb regions [27], was subsequently analyzed by Yaffe and
Tanay [28] to eliminate various biases in experimental
procedure.
In this study, we postulated that remotely acting regu-
latory elements might occur within DNA fragments that
interact with the DNA fragment containing the NF1
gene, and further that these elements might be located
within an H3K27ac-enriched region. We first combined
long-range DNA-DNA interaction data and ENCODE
resources to predict in silico the location of novel remotely
acting regulatory regions upstream of the NF1 gene. Fi-
nally, we screened these regions for mutation in those
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either the NF1 or SPRED1 genes. Germline mutations
in the SPRED1 gene have previously been detected in
individuals with clinical features overlapping those of
NF1 patients [6].Results and discussion
The Hi-C data indicated that a 1-Mb fragment of chromo-
some 17, starting at position 29,000,000 and ending at
position 29,999,999, termed the NF1-containing fragment
since it contained the entire NF1 gene (positions 29,421,
945–29,709,134), was found to interact most strongly
with the adjacent 1-Mb fragment on chromosome 17 (703
and 255 intra-chromosomal interactions with the NF1-
containing fragment recorded in HindIII- and NcoI-maps,
respectively) which occupies positions 28,000,000–28,999,
999 upstream of the NF1-containing fragment (Figure 1).
The ENCODE data indicated the presence of an H3K27
ac-enriched region somewhere between positions 28,846,
790 and 28,847,790 in the interacting fragment (region A
in Figure 1). This region is distal (approximately 600 kb
upstream) to the NF1 gene. Another peak in H3K27ac
enrichment was observed within the NF1-containing
fragment (region B between positions 29,378,421 and
29,379,750) which is proximal (approximately 42 kb) to
the NF1 gene. The level of enrichment was higher in the
distal region A than in the proximal region B. ENCODE
data also revealed the presence in region A of three over-
lapping binding sites for the transcription factors, p300
(positions 28,846,840–28,847,158), c-Fos (28,846,815–28,
847,158) and c-Jun (28,846,819–28,847,094), all of which
were identified by in vitro ChIP-seq assay (http://genome.
ucsc.edu/index.html).Figure 1 Schematic of the occurrence and level of H3K27ac enrichme
level of enrichment is shown by the height of the curves (not to scale).Two sets of primers (Table 1) were designed using
Primer3 software [29]. These were used for the polymer-
ase chain reaction (PCR) amplification and sequencing
of the two regions of interest: region A (positions 28,846,
790–28,847,790) and region B (positions 29,378,421–29,
379,750), from the genomic DNA of 47 NF1 patients as
described in the ‘Methods’ section.
Three sequence variants were identified in the distal
region, the region that corresponds to the highest level
of histone H3K27ac enrichment. DNA sequencing revealed
the presence of a heterozygous novel C>T variant at
position 28,846,793 in two NF1 patients. This variant is
not present in the dbSNP database (http://www.ncbi.
nlm.nih.gov/sites/entrez?db=snp). Two other variants,
rs78190160 (position 28,847,605) and rs71372224 (pos-
ition 28,846,883), were detected each in three different
patients. Both of these variants are listed in dbSNP as
being of unknown clinical significance; minor allele fre-
quency/minor allele count based on 1000 Genomes Project
data was 0.007/16, indicating that they are rare variants.
Unfortunately, no linkage disequilibrium data (HapMap
Project; http://hapmap.ncbi.nlm.nih.gov/) were available
for this region. The rs71372224 SNP was however
found to occur within the three overlapping binding sites
for transcription factors p300, c-Fos and c-Jun. Recent
studies [30] have shown that enhancer elements have a
high propensity to be bound by p300, an enhancer-bind-
ing transcription factor. One may therefore speculate
that a mutation in this putative enhancer element could
influence the expression of the NF1 gene in a spatially
specific manner. No variants were found in the H3K27ac-
enriched region (region B) lying proximal to the NF1 gene
region and corresponding to the lower level of H3K27ac
enrichment.nt within interacting and NF1-containing DNA fragments. The
Table 1 List of primers used to amplify and sequence
DNA regions A (28,846,790–28,847,790) and B
(29,378,421–29,379,750)
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This pilot study has shown that a combination of long-
range DNA sequence interaction data and information
about the location of functional elements available from
ENCODE allows us to predict the possible location of
novel regulatory regions that may act at distance from the
genes whose expression they might influence. Mutations
in these regions may in turn modulate the expression of
their cognate target gene(s) that are spatially close to these
regions. Although the functional ascertainment of these
variants far upstream of the NF1 gene has not yet been
performed, the type of in silico analysis described here
served to guide the mutation screening procedure, al-
lowing us to detect sequence variants in five unrelated
patients in whom no pathogenic mutations had previously
been found in either the NF1 gene or the SPRED1 gene
[6]. Even if eventually none of the detected sequence
variants turn out to be of pathogenic significance, the
Hi-C data indicate that several other 1-Mb fragments have
a high number of interactions with the NF1-containing
fragment and could potentially harbour remotely acting
regulatory elements. Among them are two 1-Mb frag-
ments occurring 1 Mb (positions 31,000,000–31,999,999)
and 2 Mb (positions 32,000,000–32,999,999) downstream
of the NF1-containing fragment that have, respectively,
699 and 150 intra-chromosomal interactions with the
NF1-containing fragment in the NcoI-map and, respect-
ively, 222 and 59 interactions in the HindIII-map. Another,
albeit weaker, inter-chromosomal interaction (21 inter-
actions in the NcoI-map) was recorded between the NF1-
containing fragment and a 1-Mb fragment on chromosome
1 (positions 1–1,999,999). Hence, applicability of this ap-proach is not only confined to cis-acting regulatory elements
but could also be employed with trans-acting regulatory
elements. The use of additional information that recently
became available through the ENCODE resources, i.e. on
the occurrence of CTCF binding factors linked to a range
of gene regulatory functions including enhancer-blocking
activity of insulator elements; DNase I hypersensitive sites
characterizing open chromatin conformations, etc., may
help to improve the in silico prediction of remotely acting
regulatory elements. This approach therefore promises
to be of potential utility in investigating those other




A sample of 47 unrelated NF1 patients (out of a total of
624 NF1 patients studied in our diagnostic centre), who
tested negative for NF1 (and SPRED1) point mutations and
intra-genic insertions/deletions, was selected for this study.
This project was approved by the local Ethics committee.
Informed consent for sample collection was obtained
according to the protocols approved by this committee.
Bioinformatics analysis
Long-range chromosomal DNA sequence interaction data
were downloaded from http://compgenomics.weizmann.
ac.il/tanay/?page_id=283. These data comprised the Hi-C
contact maps [27], normalized to eliminate various biases
associated with the experimental procedure [28]. Two ma-
trices of interactions between 1-Mb fragments, each
combining the results obtained using, respectively, the
restriction enzymes HindIII and NcoI in the experimental
procedures, were available. Henceforth, these contact
maps will be termed, respectively, the HindIII- and NcoI-
maps. Information on the genome-wide occurrence of
one particular functional element, the histone H3K27ac-
enriched region, was downloaded from the ENCODE
database available at http://genome.ucsc.edu/index.html.
The NF1 gene, spanning positions 29,421,945–29,709,
134 from pter of chromosome 17 (NCBI build 37, UCSC
HG18 and Ensembl GRCh37), occurs almost in the
middle of a 1-Mb DNA fragment that starts at position
29,000,000 and ends at position 29,999,999. This 1-Mb
fragment will henceforth be termed the NF1-containing
fragment. Two of the contact maps described above were
searched for DNA fragments, whether occurring on the
same chromosome or on different chromosomes that had
the most interactions with the NF1-containing fragment.
Data on the occurrence and level of H3K27ac enrich-
ment (as measured by the ChIP-seq assay) within the
1-Mb fragment that had the strongest interaction with
the NF1-containing fragment were downloaded from the
ENCODE database. H3K27ac data were also downloaded
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1-Mb fragments (i.e. the fragment that had the strongest
interaction with the NF1-containing fragment and the
NF1-containing fragment itself), relatively short regions,
corresponding to the highest level of H3K27ac enrich-
ment, termed regions A and B, respectively, were selected
for DNA sequencing in 47 NF1 patients in whom no
pathogenic mutations had been found by screening
both the NF1 and SPRED1 genes.
PCR and sequencing
Two sets of primers for regions A and B, selected as
described above, were designed using Primer3 software
[29] and purchased from Eurogentec (Southampton,
UK). Specificity was confirmed by BLAST analysis.
The genomic DNA isolated from the peripheral blood
cells of the NF1 patients was subjected to PCR and
Sanger sequencing as described [31]. PCR reaction mix-
tures of 25 μl contained 5 μl of genomic DNA (6 ng/μl),
5 pmol each of the forward and reverse primers, 0.25 U
AmpliTaq Gold polymerase, 3 mM MgCl2, PCR buffer
and 0.125 mM each dNTP. PCR cycling conditions were
95°C for 10 min followed by 40 cycles of 95°C × 30 s,
60°C × 30 s, 72°C × 30 s with a final extension step of
72°C for 10 min. PCR fragments were confirmed by gel
electrophoresis in 1.5% agarose gels and visualized with
ethidium bromide staining. The sequencing of the PCR
products was performed with BigDye Terminator v3.1
Cycle Sequencing Kits and run on an ABI 3730 genetic
analyzer. The obtained sequences were analyzed using
Sequencher software version 4.7 (Gene Codes Corp.,
Ann Arbor, MI, USA). All reagents were purchased from
Life Technologies Ltd, Paisley, UK.
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